The group receiving SRP+MTZ+AMX presented greater mean probing depth ( PD ) reduction and clinical attachment gain , a lower number of sites with PD @mm ( primary outcome variable ) and a reduced number of subjects with @ of these residual pockets than the control group at @-year post-therapy ( p < @ ) .